Patients with polycystic kidney disease and polycystic liver disease randomized to treatment with lanreotide were associated with a reduction in liver volume compared to standard of care, a researcher said here. Height-adjusted liver volume declined 1.99% (95% CI -4.21 to 0.24) in the lanreotide group compared to an increase of 3.92% with standard of care (95% CI 1.56-6.28), for a difference of -5.91% (95% CI -9.18 to -2.63, P<0.001), reported a MD of Radboud University Medical Center in Nijmegen , the Netherlands van Aerts explained that polycystic liver disease is the most frequent extra-renal manifestation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) at a press conference at the European Association for the Study of the Liver (EASL) annual meeting.
"Polycystic kidney and liver disease patients will have renal cysts, but the majority also possess liver cysts ... and you can…
